Market: NASD |
Currency: USD
Address: 149 Fifth Avenue
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Show more
📈 MiNK Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$39.00
-
Upside/Downside from Analyst Target:
161.74%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-0.96
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.100000 |
- |
2025-01-28 |
- |
Stock split |
|
Total Amount for 2025: $0.100000 |
📅 Earnings & EPS History for MiNK Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-14 | -1.06 |
| 2025-05-15 | -0.7 |
| 2025-03-18 | -0.62 |
| 2024-11-14 | -0.5 |
| 2024-08-13 | -0.7 |
| 2024-05-14 | -1.1 |
| 2024-03-21 | -1.5 |
| 2023-11-09 | -1.5 |
| 2023-08-10 | -1.8 |
| 2023-05-11 | -1.7 |
| 2023-03-21 | -2.3 |
| 2022-11-03 | -1.9 |
| 2022-08-09 | -1.8 |
| 2022-05-13 | -2.3 |
| 2022-03-18 | -1.8 |
| 2021-11-29 | -5.9 |
📰 Related News & Research
No related articles found for "mink therapeutics".
